NIH PAR · NCI · R01
PAR-27-072: Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This Notice of Funding Opportunity (NOFO) encourages collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or…
- NOFO number
- PAR-27-072
- Type
- PAR
- Activity code
- R01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Optional
- Posted
- May 4, 2026
- Opens
- Sep 5, 2026
- Expires
- Jul 6, 2029
PAR-27-072 due dates
8 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| October 05, 2026 * | November 05, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 05, 2027 * | March 05, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 05, 2027 * | July 05, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 05, 2027 * | November 05, 2027 * | Not Applicable | March 2028 | May 2028 | July 2028 |
| February 05, 2028 * | March 05, 2028 * | Not Applicable | July 2028 | October 2028 | December 2028 |
| June 05, 2028 * | July 05, 2028 * | Not Applicable | November 2028 | January 2029 | April 2029 |
| October 05, 2028 * | November 05, 2028 * | Not Applicable | March 2029 | May 2029 | July 2029 |
| February 05, 2029 * | March 05, 2029 * | Not Applicable | July 2029 | October 2029 | December 2029 |
| June 05, 2029 * | July 05, 2029 * | Not Applicable | November 2029 | January 2030 | April 2030 |
What its predecessor PAR-22-243 funded
PAR-27-072 reissues PAR-22-243. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 13 projects and $24.6M in FY2022–FY2026.
Projects funded
13
Distinct projects, FY2022–FY2026
New awards
11
Type 1 (new project) award records
NIH funding
$24.6M
Award dollars under PAR-22-243, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 1 | 1 | $747K |
| FY2024 | 8 | 6 | $4.9M |
| FY2025 | 13 | 4 | $10.4M |
| FY2026 | 10 | 0 | $8.5M |
Institutions with the most funding
- Brigham and Women's Hospital$6.2M · 2 projects
- University of Arizona$3.3M · 1 project
- University of Wisconsin-Madison$3.0M · 1 project
- University of Michigan at Ann Arbor$2.6M · 2 projects
- Northwestern University$2.1M · 1 project
- Johns Hopkins University$1.8M · 1 project
- University of Houston$1.4M · 1 project
- Case Western Reserve University$1.3M · 1 project
Most recent new awards
- Efficient Measurement and Characterization of Genetic Interactions in Cancer Cells (opens NIH RePORTER)
University of Tx MD Anderson Can Ctr · 1R01CA303638-01 · NCI · Notice Sep 8, 2025
$370KR01
- Magnetic Resonance Fingerprinting of Glutamate Metabolism for Guiding Glioma Cancer Care (opens NIH RePORTER)
Brigham and Women's Hospital · 1R01CA296008-01A1 · NCI · Notice Aug 14, 2025
$3.2MR01
- Development of optimal sensory feedback strategies to maximize function after tetraplegia (opens NIH RePORTER)
Case Western Reserve University · 1R01HD117313-01 · NICHD · Notice Jul 23, 2025
$619KR01
- Towards Efficient Personalization of Computerized Lower Limb Prostheses via Reinforcement Learning in a Clinical Setup (opens NIH RePORTER)
North Carolina State University Raleigh · 1R01HD116422-01A1 · NICHD · Notice Jul 17, 2025
$630KR01
- Enhancing radioligand therapy for prostate cancer with biomarker and dosimetry guided personalization (opens NIH RePORTER)
University of Michigan at Ann Arbor · 1R01CA289631-01 · NCI · Notice Sep 17, 2024
$645KR01
- MINT conditioning to improve post-stroke gait (opens NIH RePORTER)
Northwestern University · 1R01HD113270-01A1 · NICHD · Notice Jul 24, 2024
$690KR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
3 NIH institutes and offices take applications under PAR-27-072. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- NEI · National Eye Institute
- NICHD · Eunice Kennedy Shriver National Institute of Child Health and Human Development
Related notices
NIH lists no related notices for PAR-27-072 yet.
Award terms
- Application types allowed
- New Renewal Resubmission Revision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to less than 500,000 direct costs) per year.
- Project period
- The scope of the proposed project should determine the project period. The maximum award period is 5 years depending on the policy of each NIH Institute. Applicants are encouraged to review the current funding policy of each NIH Institute. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-22-243.
Other open NOFOs for R01
- PAR-25-336Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)NCI · next due Nov 16, 2026
- PAR-25-337Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-338Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PAR-25-243Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PA-25-172Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-24-311Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.